Botanical guide · Ingredient reference

Ginkgo in a child ADHD trial: less effective than the active comparator

A six-week trial found ginkgo less effective than methylphenidate on parent and teacher ADHD ratings. Fewer selected adverse effects did not make the treatments equivalent.

Read the evidence ↓

Supplement Science Insights Editorial Team

Published September 23, 2026

Study and results

Fifty children and adolescents entered a randomized, double-blind comparison of a specified ginkgo product and methylphenidate. Doses varied by weight, and ratings were collected at baseline and during treatment. [1]

Parent and teacher scores improved more with methylphenidate. Decreased appetite, headache and insomnia were reported more frequently with methylphenidate; other reported adverse-effect frequencies did not significantly differ. [1]

Interpretation and limitations

This was a small, short active-comparator study, not a general pediatric safety assessment. It does not establish a home dose or a substitute for ADHD care. Funding and conflicts were not established from the retrieved abstract. [1]

A hypothetical distinction

Imagine one treatment has fewer reports of a particular side effect but also much less symptom benefit. Both findings belong in the comparison.

Evidence summary — Ginkgo in a child ADHD trial
DetailInterpretation
Symptom ratingsFavored comparator
Selected adverse effectsSeparate outcome
Long-term child safetyNot established
Ginkgo in a child ADHD trial: less effective than the active comparator — original article outline diagram
Original editorial diagram of this article’s sections; no product photograph or clinical finding is depicted.

Sources for this article

  1. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial - PubMed
    Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.